Novo Nordisk recently announced its intention to seek regulatory approval for the use of semaglutide, the active ingredient in its profitable weight loss drug, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). This decision came after a Phase 3 clinical trial yielded
In a landmark event for Denmark’s technology landscape, the nation's first AI supercomputer, Gefion, has been officially inaugurated. This momentous occasion promises to expedite drug discovery and address a variety of societal challenges. The Novo Nordisk Foundation, a principal player in the
Artificial Intelligence (AI) has the potential to revolutionize drug discovery and development, offering numerous advantages that could transform current practices in the biopharmaceutical industry. By merging Accenture's advanced capabilities in AI scaling with the innovative ITO™ platform d
In a pioneering move to advance cancer treatment, Ryvu Therapeutics and nCage Therapeutics have announced a research collaboration aimed at developing a next-generation antibody-drug conjugate (ADC) platform. This partnership promises to leverage nCage's TRAP cage platform, a novel drug
The recent FDA approval of Protega Pharmaceuticals Inc.'s ROXYBOND (oxycodone hydrochloride) immediate-release (IR) CII 10 mg tablet marks a significant milestone in managing severe pain where alternative treatments fall short. ROXYBOND 10 mg stands out as the first FDA-approved
Kapoose Creek Bio, a biotechnology firm well-versed in AI-driven natural product drug discovery, has made a significant leap forward with its latest acquisition. The company has secured an exclusive license to the chemical informatics platform of Adapsyn Bioscience and acquired Adapsyn's drug
